Lyme disease vaccine reduces risk by more than 70% in study
statnews.com • • business
Key Points:
- Pfizer and Valneva's experimental Lyme disease vaccine demonstrated over 70% effectiveness in reducing the risk of developing the infection, based on newly released data.
- Although the results did not meet a key statistical benchmark, the companies plan to seek regulatory approval for the vaccine.
- Lyme disease affects approximately 476,000 people annually in the U.S. and 132,000 in Europe, with symptoms ranging from rash and fatigue to serious joint, heart, and nerve complications if untreated.
- The vaccine could become an important preventive tool against this tick-borne bacterial infection.
